Last reviewed · How we verify
NCT01108692: SETAM
Investigation on Early Detection and Active Management of Supra-ventricular Arrhythmia With Telecardiology
NA trial testing Telecardiology in Atrial Fibrillation in 602 participants. Completed in 1 November 2013.
1 July 2013
Quick facts
| Lead sponsor | Biotronik France |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 602 |
| Start date | 1 July 2010 |
| Primary completion | 1 July 2013 |
| Estimated completion | 1 November 2013 |
| Sites | 57 locations across France |
Drugs / interventions tested
- Telecardiology
Conditions studied
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
- Atrial Flutter — all drugs for Atrial Flutter →
- Atrial Tachycardia — all drugs for Atrial Tachycardia →
Sponsor
Biotronik France
Who can join
18 and older, any sex, with Atrial Fibrillation or Atrial Flutter. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Delay to implement antithrombotic and/or antiarrhythmic drugs for the supraventricular arrhythmia.
Time frame: 12-month
Delay from enrollment until the next in-office follow-up during which the supraventricular arrhythmia is managed for the first-time.
Sponsor's own description
This study investigates if the early detection and treatment of supraventricular arrhythmia (SVA) may help to prevent the progression of the arrhythmia and improve the clinical outcome. The primary endpoint investigates the delay to implement treatment in two groups of patients : * Active group: Patients followed by telecardiology. * Control group: Patients followed in the conventional manner. It is assumed that the delay to implement treatment will be higher in the Control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01108692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atrial Fibrillation
Currently open trials in the same condition.
- NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
- NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
- NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
- NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01108692 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biotronik France
- Last refreshed: 5 December 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01108692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing